Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting

Richard Kim, MD

Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting

ESMO Highlights

Videos — September 29, 2021

Featuring:

Richard Kim, MD

Service Chief, Medical Gastrointestinal Oncology
Senior Member, Gastrointestinal Oncology Department
Moffitt Cancer Center
Professor, Oncology
University of South Florida College of Medicine
Tampa, FL

Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.

Related Items

2022 Year in Review: Cholangiocarcinoma

By Richard Kim, MD

Cholangiocarcinoma

2022 Year in Review: Cholangiocarcinoma

In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial

ESMO Highlights

Web Exclusives

Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.

Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2

ESMO Highlights

Web Exclusives

Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.

Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations

ESMO Highlights

Web Exclusives

Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.

FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA

ESMO Highlights

Web Exclusives

Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.

Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC

ESMO Highlights

Web Exclusives

The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.

Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers

ESMO Highlights

Web Exclusives

A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.

Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC

ESMO Highlights

Web Exclusives

Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.

ESMO Highlights

Web Exclusives

Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.

CCA Summit Live from ESMO 2022

By Juan W. Valle, MB ChB, MSc, FRCP

ESMO Highlights

Videos

On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.

Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know